@article{MTMT:34410430,
	title = {Cytoplasmic aggregation of RPB1 predicts failure of neoadjuvant chemotherapy against invasive carcinoma of no special type},
	url = {https://m2.mtmt.hu/api/publication/34410430},
	author = {Vörös, András and Nagy-Mikó, Bence and Oláh, Orsolya and Pankotai, Tibor and Újfaludi, Zsuzsanna and Nikolényi, Alíz and Lázár, György ifj and Ormandi, K and Villanyi, Zoltan},
	journal-iso = {VIRCHOWS ARCH},
	journal = {VIRCHOWS ARCHIV},
	volume = {483},
	unique-id = {34410430},
	issn = {0945-6317},
	year = {2023},
	eissn = {1432-2307},
	pages = {S170-S171},
	orcid-numbers = {Vörös, András/0000-0001-6837-0567; Oláh, Orsolya/0000-0002-5731-4030; Pankotai, Tibor/0000-0001-9810-5465; Újfaludi, Zsuzsanna/0000-0003-4738-0963; Lázár, György ifj/0000-0001-7155-2978}
}

@article{MTMT:34230980,
	title = {Predictive Potential of RNA Polymerase B (II) Subunit 1 (RPB1) Cytoplasmic Aggregation for Neoadjuvant Chemotherapy Failure},
	url = {https://m2.mtmt.hu/api/publication/34230980},
	author = {Nagy-Mikó, Bence and Szatmári, Orsolya and Faragó-Mészáros, Réka and Csókási, Aliz and Bognár, Bence and Ördög, Nóra and Borsos, Barbara Nikolett and Majoros, Hajnalka and Újfaludi, Zsuzsanna and Oláh, Orsolya and Nikolényi, Alíz and Dobi, Ágnes and Kószó, Renáta Lilla and Sántha, Dóra and Lázár, György ifj and Simonka, Zsolt and Paszt, Attila and Ormándi, Katalin and Pankotai, Tibor and Boros, Imre Miklós and Villanyi, Zoltan and Vörös, András},
	doi = {10.3390/ijms242115869},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {34230980},
	issn = {1661-6596},
	abstract = {We aimed to investigate the contribution of co-translational protein aggregation to the chemotherapy resistance of tumor cells. Increased co-translational protein aggregation reflects altered translation regulation that may have the potential to buffer transcription under genotoxic stress. As an indicator for such an event, we followed the cytoplasmic aggregation of RPB1, the aggregation-prone largest subunit of RNA polymerase II, in biopsy samples taken from patients with invasive carcinoma of no special type. RPB1 frequently aggregates co-translationally in the absence of proper HSP90 chaperone function or in ribosome mutant cells as revealed formerly in yeast. We found that cytoplasmic foci of RPB1 occur in larger sizes in tumors that showed no regression after therapy. Based on these results, we propose that monitoring the cytoplasmic aggregation of RPB1 may be suitable for determining—from biopsy samples taken before treatment—the effectiveness of neoadjuvant chemotherapy.},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Ördög, Nóra/0000-0003-1931-4053; Majoros, Hajnalka/0000-0003-2020-971X; Újfaludi, Zsuzsanna/0000-0003-4738-0963; Oláh, Orsolya/0000-0002-5731-4030; Kószó, Renáta Lilla/0000-0002-1958-7839; Lázár, György ifj/0000-0001-7155-2978; Simonka, Zsolt/0000-0002-3490-226X; Paszt, Attila/0000-0002-1637-8652; Pankotai, Tibor/0000-0001-9810-5465; Boros, Imre Miklós/0000-0001-8504-9687; Vörös, András/0000-0001-6837-0567}
}

@article{MTMT:34181323,
	title = {The term “classic invasive lobular carcinoma” of the breast defines breast malignancies of vastly different nature},
	url = {https://m2.mtmt.hu/api/publication/34181323},
	author = {Tabár, László and Dean, Peter B. and Ming-Fang Yen, Amy and Yi-Ying Wu, Wendy and Tarján, Miklós and Lee Tucker, F. and Hsiu-Hsi Chen, Tony and Vörös, András},
	doi = {10.1016/j.ejrad.2023.111119},
	journal-iso = {EUR J RADIOL},
	journal = {EUROPEAN JOURNAL OF RADIOLOGY},
	volume = {168},
	unique-id = {34181323},
	issn = {0720-048X},
	year = {2023},
	eissn = {1872-7727},
	orcid-numbers = {Vörös, András/0000-0001-6837-0567}
}

@article{MTMT:34172032,
	title = {TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin},
	url = {https://m2.mtmt.hu/api/publication/34172032},
	author = {Almási, Szintia and Kuthi, Levente and Sejben, Anita and Vörös, András and Nagy, Ákos and Zombori, Tamás and Cserni, Gábor},
	journal-iso = {VIRCHOWS ARCH},
	journal = {VIRCHOWS ARCHIV},
	volume = {483},
	unique-id = {34172032},
	issn = {0945-6317},
	year = {2023},
	eissn = {1432-2307},
	pages = {S57-S57},
	orcid-numbers = {Kuthi, Levente/0000-0001-9247-6679; Sejben, Anita/0000-0002-9434-2989; Vörös, András/0000-0001-6837-0567; Zombori, Tamás/0000-0002-0654-563X; Cserni, Gábor/0000-0003-1344-7744}
}

@article{MTMT:34120913,
	title = {Imaging biomarkers are underutilised but highly predictive prognostic factors for the more fatal breast cancer subtypes},
	url = {https://m2.mtmt.hu/api/publication/34120913},
	author = {Tabár, László and Dean, Peter B. and Tucker, F. Lee and Yen, Amy Ming-Fang and Chen, Sam Li-Sheng and Lin, Abbie Ting-Yu and Hsu, Chen-Yang and Munpolsri, Pattaranan and Wu, Wendy Yi-Ying and Smith, Robert A. and Duffy, Stephen W. and Chen, Tony Hsiu-Hsi and Tarján, Miklós and Vörös, András},
	doi = {10.1016/j.ejrad.2023.111021},
	journal-iso = {EUR J RADIOL},
	journal = {EUROPEAN JOURNAL OF RADIOLOGY},
	volume = {166},
	unique-id = {34120913},
	issn = {0720-048X},
	abstract = {Purpose: The development and refinement of breast imaging modalities offer a wealth of diagnostic information such as imaging biomarkers, which are primarily the mammographic appearance of the various breast cancer subtypes. These are readily available preoperatively at the time of diagnosis and can enhance the prognostic value of currently used molecular biomarkers. In this study, we investigated the relative utility of the molecular and imaging biomarkers, both jointly and independently, when predicting long-term patient outcome according to the site of tumour origin.Methods: We evaluated the association of imaging biomarkers and conventional molecular biomarkers, (ER, PR, HER-2, Ki67), separately and combined, with long-term patient outcome in all breast cancer cases having complete data on both imaging and molecular biomarkers (n = 2236) diagnosed in our Institute during the period 2008-2019. Large format histopathology technique was used to document intra- and intertumoural het-erogeneity and select the appropriate foci for evaluating molecular biomarkers.Results: The breast cancer imaging biomarkers were strongly predictive of long-term patient outcome. The mo-lecular biomarkers were predictive of outcome only for unifocal acinar adenocarcinoma of the breast (AAB), but less reliable in the multifocal AAB cases due to variability of molecular biomarkers in the individual tumour foci. In breast cancer of mesenchymal origin (BCMO), conventionally termed classic invasive lobular carcinoma, and in cancers originating from the major lactiferous ducts (ductal adenocarcinoma of the breast, DAB), the mo-lecular biomarkers misleadingly indicated favourable prognosis, whereas the imaging biomarkers in BCMO and DAB reliably indicated the high risk of breast cancer death. Among the 2236 breast cancer cases, BCMO and DAB comprised 21% of the breast cancer cases, but accounted for 45% of the breast cancer deaths.Conclusions: Integration of imaging biomarkers into the diagnostic workup of breast cancer yields a more precise, comprehensive and prognostically accurate diagnostic report. This is particularly necessary in multifocal AAB cases having intertumoural heterogeneity, in diffuse carcinomas (DAB and BCMO), and in cases with combined DAB and AAB. In such cases, the imaging biomarkers should be prioritised over molecular biomarkers in planning treatment because the latter fail to predict the severity of the disease. In combination with the use of the large section histopathology technique, imaging biomarkers help alleviate some of the current problems in breast cancer management, such as over-and under-assessment of disease extent, which carry the risk of overtreatment and undertreatment.},
	keywords = {Breast Neoplasms; interdisciplinary communication; patient care; Mammography; Early Detection of Cancer; PATHOLOGISTS; Precision Medicine; Molecular biomarkers; Imaging biomarkers; Radiology, Nuclear Medicine & Medical Imaging; Histopathology technology},
	year = {2023},
	eissn = {1872-7727},
	orcid-numbers = {Vörös, András/0000-0001-6837-0567}
}

@article{MTMT:34068499,
	title = {Does Diffusely Infiltrating Lobular Carcinoma of the Breast Arise from Epithelial-Mesenchymal Hybrid Cells?},
	url = {https://m2.mtmt.hu/api/publication/34068499},
	author = {Tabár, László and Bozó, Renáta and Dean, Peter B and Ormándi, Katalin and Puchkova, Olga and Oláh, Orsolya and Németh, István Balázs and Veréb, Zoltán and Yen, Ming-Fang and Chen, Li-Sheng and Chen, Hsiu-Hsi and Vörös, András},
	doi = {10.3390/ijms241310752},
	journal-iso = {INT J MOL SCI},
	journal = {INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES},
	volume = {24},
	unique-id = {34068499},
	issn = {1661-6596},
	abstract = {Classic diffusely infiltrating lobular carcinoma has imaging features divergent from the breast cancers originating from the terminal ductal lobular units and from the major lactiferous ducts. Although the term "invasive lobular carcinoma" implies a site of origin within the breast lobular epithelium, we were unable to find evidence supporting this assumption. Exceptional excess of fibrous connective tissue and the unique cell architecture combined with the aberrant features at breast imaging suggest that this breast malignancy has not originated from cells lining the breast ducts and lobules. The only remaining relevant component of the fibroglandular tissue is the mesenchyme. The cells freshly isolated and cultured from diffusely infiltrating lobular carcinoma cases contained epithelial-mesenchymal hybrid cells with both epithelial and mesenchymal properties. The radiologic and histopathologic features of the tumours and expression of the mesenchymal stem cell positive markers CD73, CD90, and CD105 all suggest development in the direction of mesenchymal transition. These hybrid cells have tumour-initiating potential and have been shown to have poor prognosis and resistance to therapy targeted for malignancies of breast epithelial origin. Our work emphasizes the need for new approaches to the diagnosis and therapy of this highly fatal breast cancer subtype.},
	keywords = {Biomarkers; Breast Neoplasms; interdisciplinary communication; patient care; Mammography; Early Detection of Cancer; PATHOLOGISTS; precision oncology; neoplastic stem cell; Histopathology technology},
	year = {2023},
	eissn = {1422-0067},
	orcid-numbers = {Bozó, Renáta/0000-0003-4242-2474; Oláh, Orsolya/0000-0002-5731-4030; Veréb, Zoltán/0000-0002-9518-2155; Vörös, András/0000-0001-6837-0567}
}

@article{MTMT:33936269,
	title = {Multifocal and diffusely infiltrating breast cancers are highly fatal subgroups needing further improvement in diagnostic and therapeutic strategies},
	url = {https://m2.mtmt.hu/api/publication/33936269},
	author = {Tabár, László and Dean, Peter B. and Tucker, F. Lee and Yen, Amy Ming-Fang and Chen, Tony Hsiu-Hsi and Wu, Wendy Yi-Ying and Vörös, András},
	doi = {10.1016/j.ejrad.2023.110854},
	journal-iso = {EUR J RADIOL},
	journal = {EUROPEAN JOURNAL OF RADIOLOGY},
	volume = {164},
	unique-id = {33936269},
	issn = {0720-048X},
	year = {2023},
	eissn = {1872-7727},
	orcid-numbers = {Dean, Peter B./0000-0003-0757-9054; Vörös, András/0000-0001-6837-0567}
}

@article{MTMT:33748939,
	title = {Can we improve breast cancer management using an image-guided histopathology workup supported by larger histopathology sections?},
	url = {https://m2.mtmt.hu/api/publication/33748939},
	author = {Tabár, László and Dean, Peter B. and Lee Tucker, F. and Vörös, András},
	doi = {10.1016/j.ejrad.2023.110750},
	journal-iso = {EUR J RADIOL},
	journal = {EUROPEAN JOURNAL OF RADIOLOGY},
	volume = {161},
	unique-id = {33748939},
	issn = {0720-048X},
	year = {2023},
	eissn = {1872-7727},
	orcid-numbers = {Vörös, András/0000-0001-6837-0567}
}

@misc{MTMT:33733107,
	title = {TRPS1 emlőmarker expressziójának vizsgálata és értékelése cytokeratin 5 pozitív, tripla negatív emlőrákokban},
	url = {https://m2.mtmt.hu/api/publication/33733107},
	author = {Almási, Szintia and Kuthi, Levente and Sejben, Anita and Vörös, András and Nagy, Ákos and Zombori, Tamás and Cserni, Gábor},
	unique-id = {33733107},
	abstract = {Célkitűzés
		Tripla negatív emlőrákok (TNBC) esetében az ösztrogén- és progeszteronreceptor, valamint a humán epidermális növekedési faktor receptor-2 (HER-2) expresszió hiánya figyelhető meg. A TNBCk túlnyomó része agresszív tumor, magas metasztatikus potenciállal. Jellemző rájuk az is, hogy kevésbé expresszálnak olyan markereket, melyek a metasztázisból lehetővé tennék a primer tumor, azaz az emlő eredet igazolását. Az eddig ismert emlőmarkerek, mint a gross cystic disease fluid protein-15 (GCDPF-15), a GATA binding protein 3 (GATA3), a mammaglobin (MGB) és a SRY-related HMG-box 10 (SOX10) nem kellően specifikusak emlőrákokra. A célunk a trichorhinophalangeal syndrome type 1 (TRPS1), mint lehetséges emlőmarker vizsgálata tripla negatív, cytokeratin 5 pozitív (CK5+) emlőrákokban, valamint a TRPS1 expresszió értékelésének reprodukálhatósága volt. 
		Módszer
		Százhúsz tripla negatív emlőrákból készült tissue microarray (TMA) blokkok TRPS1 immunhisztokémiai festődését vizsgálatuk. A pozitivitás küszöbértéke legalább 10%-os nukleáris festődés volt, ennek reprodukálhatóságát is vizsgáltuk kappa statisztikával. A minták GATA3, GCDFP-15, MGB és SOX10 pozitivitására vonatkozó adatokat korábbi vizsgálatainkból nyertük. 
		Eredmények
		Száztizenhét minta lett értékelhető. TRPS1 pozitivitás 92 (79%) esetben volt, ami felülmúlja a korábban tesztelt markereket, melyekben a következőképpen alakult a pozitivitás: SOX10: 82 (70%), GATA3: 11 (9%), MGB: 10 (9%) és GCDFP-15: 7 (6%). A 25 TRPS1 negatív esetből 11 pozitívnak bizonyult SOX10 immunhisztokémiával. A TRPS1, illetve SOX10 kettős negatív esetekből 5 bizonyult pozitívnak egyéb markerekkel. A reprodukálhatóság tekintetében a TRPS1 expresszió esetében jelentős véleményegyezést tapasztaltunk (Cohen kappa: 0,67).
		Megbeszélés
		Az 5 vizsgált markerből a TRPS1 bizonyult legszenzitívebb emlő eredetet igazoló markernek, a CK5+ TNBCk kapcsán. A TRPS1 negatív esetek túlnyomó része SOX10 pozitivitást mutatott, a fennmaradó dupla negatív esetek egy része viszont pozitívnak bizonyult GCDFP15 és/vagy MGB markerekkel.},
	year = {2023},
	orcid-numbers = {Kuthi, Levente/0000-0001-9247-6679; Sejben, Anita/0000-0002-9434-2989; Vörös, András/0000-0001-6837-0567; Zombori, Tamás/0000-0002-0654-563X; Cserni, Gábor/0000-0003-1344-7744}
}

@article{MTMT:33731548,
	title = {TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin},
	url = {https://m2.mtmt.hu/api/publication/33731548},
	author = {Almási, Szintia and Kuthi, Levente and Sejben, Anita and Vörös, András and Nagy, Ákos and Zombori, Tamás and Cserni, Gábor},
	doi = {10.1007/s00428-023-03535-4},
	journal-iso = {VIRCHOWS ARCH},
	journal = {VIRCHOWS ARCHIV},
	volume = {482},
	unique-id = {33731548},
	issn = {0945-6317},
	abstract = {The lack of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 expression in breast cancer (BC) is the basis for the categorization of the tumour as triple negative breast carcinoma (TNBC). The majority of TNBCs are aggressive tumours with common metastases and decreased expression of markers that could help in identifying the metastatic lesion as of mammary origin. Breast markers, such as gross cystic disease fluid protein-15 (GCDPF-15), GATA binding protein 3 (GATA3), mammaglobin (MGB) and SOX10, are not uniquely specific to BC. Our aim was to evaluate trichorhinophalangeal syndrome type 1 (TRPS1) protein as a breast marker in a series of cytokeratin-5-expressing TNBC, mostly corresponding to basal-like TNBCs, previously characterized for the expression of other breast markers. One hundred seventeen TNBCs in tissue microarrays were immunostained for TRPS1. The cut-off for positivity was ≥ 10%. The reproducibility of this classification was also assessed. TRPS1 positivity was detected in 92/117 (79%) cases, and this exceeded the expression of previously tested markers like SOX10 82 (70%), GATA3 11 (9%), MGB 10 (9%) and GCDFP-15 7 (6%). Of the 25 TRPS1-negative cases, 11 were positive with SOX10, whereas 5 to 6 dual negatives displayed positivity for the other makers. The evaluation showed substantial agreement. Of the five markers compared, TRPS1 seems the most sensitive marker for the mammary origin of CK5-expressing TNBCs. Cases that are negative are most often labelled with SOX10, and the remainder may still demonstrate positivity for any of the 3 other markers. TRPS1 has a place in breast marker panels.},
	year = {2023},
	eissn = {1432-2307},
	pages = {861-868},
	orcid-numbers = {Kuthi, Levente/0000-0001-9247-6679; Sejben, Anita/0000-0002-9434-2989; Vörös, András/0000-0001-6837-0567; Zombori, Tamás/0000-0002-0654-563X; Cserni, Gábor/0000-0003-1344-7744}
}